Janus激酶抑制剂在中重度特应性皮炎中的应用进展

doi:10.35541/cjd.20220342

Abstract

Abstract: 【Abstract】 Atopic dermatitis （AD） is a common chronic inflammatory skin disease with unclear pathogenesis. Multiple inflammatory cells and relevant cytokines are involved in its occurrence. Janus kinase（JAK） inhibitors can suppress the JAK-signal transducer and activator of transcription （STAT） signaling pathway, block the signal transduction of relevant cytokines, and reduce inflammatory responses. Currently, several JAK inhibitors have been approved for the treatment of moderate-to-severe AD, and clinical trials have demonstrated their good efficacy and safety. This review summarizes the mechanisms of action, efficacy and safety of different types of JAK inhibitors for the treatment of moderate-to-severe AD.

Key words: Dermatitis, atopic, Janus kinases, Signal transduction pathway, Efficacy, Safety

CLC Number:

Li Ming, Li Yan, Li Linfeng. JAK inhibitors for the treatment of moderate-to-severe atopic dermatitis[J]. Chinese Journal of Dermatology,2025,e0220342. doi:10.35541/cjd.20220342

References ［26］

［1］	Traidl S, Freimooser S, Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis［J］. Allergol Select, 2021,5:293⁃304. doi: 10.5414/ALX02272E.
［2］	Langan SM, Irvine AD, Weidinger S. Atopic dermatitis［J］. Lancet, 2020,396（10247）:345⁃360. doi: 10.1016/S0140⁃6736（20）31286⁃1.
［3］	Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate⁃to⁃severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase Ⅲ trials［J］. Br J Dermatol, 2020,183（2）:242⁃255. doi: 10.1111/bjd.18898.
［4］	刘擘, 宋晓婷, 廖双璐, 等. 巴瑞替尼治疗中重度特应性皮炎的疗效和安全性观察［J］. 中华皮肤科杂志, 2022,55（4）:304⁃307. doi: 10.35541/cjd.20210474.
［5］	Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial［J］. JAMA Dermatol, 2020,156（12）:1333⁃1343. doi: 10.1001/jamadermatol.2020.3260.
［6］	Silverberg JI, Simpson EL, Wollenberg A, et al. Long⁃term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials［J］. JAMA Dermatol, 2021,157（6）:691⁃699. doi: 10.1001/jamadermatol. 2021.1273.
［7］	Reich K, Simpson E, Wollenberg A, et al. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate⁃to⁃severe atopic dermatitis in a randomized substudy from the long⁃term extension study BREEZE⁃AD3［J］. Br J Dermatol. 2023,188（2）:208⁃217. doi: 10.1093/bjd/ljac057.
［8］	Guttman⁃Yassky E, Teixeira HD, Simpson EL, et al. Once⁃daily upadacitinib versus placebo in adolescents and adults with moderate⁃to⁃severe atopic dermatitis （Measure Up 1 and Measure Up 2）: results from two replicate double⁃blind, randomised controlled phase 3 trials［J］. Lancet, 2021,397（10290）:2151⁃2168. doi: 10.1016/S0140⁃6736（21）00588⁃2.
［9］	Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow⁃up data from the Measure Up 1 and Measure Up 2 randomized clinical trials［J］. JAMA Dermatol, 2022,158（4）:404⁃413. doi: 10.1001/jamadermatol.2022.0029.
［10］	Reich K, Teixeira HD, de Bruin⁃Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate⁃to⁃severe atopic dermatitis （AD Up）: results from a randomised, double⁃blind, placebo⁃controlled, phase 3 trial［J］. Lancet, 2021,397（10290）:2169⁃2181. doi: 10.1016/S0140⁃6736（21）00589⁃4.
［11］	Silverberg JI, de Bruin⁃Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results［J］. J Allergy Clin Immunol, 2022,149（3）:977⁃987.e14. doi: 10.1016/j.jaci.2021.07.036.
［12］	Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate⁃to⁃severe atopic dermatitis: a randomized clinical trial［J］. JAMA Dermatol, 2021,157（9）:1047⁃1055. doi: 10.1001/jamadermatol. 2021.3023.
［13］	Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate⁃to⁃severe atopic dermatitis: a randomized clinical trial［J］. JAMA Dermatol, 2020,156（8）:863⁃873. doi: 10.1001/jamadermatol.2020.1406.
［14］	Tong Z, Zhang Y, Zhou K, et al. An observational study of abrocitinib in adults with moderate⁃to⁃severe atopic dermatitis after switching from dupilumab［J］. J Am Acad Dermatol, 2023,89（4）:826⁃828. doi: 10.1016/j.jaad.2023. 05.077.
［15］	Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate⁃to⁃severe atopic dermatitis: The JADE TEEN randomized clinical trial［J］. JAMA Dermatol, 2021,157（10）:1165⁃1173. doi: 10.1001/jamadermatol.2021.2830.
［16］	Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis［J］. N Engl J Med, 2021,384（12）:1101⁃1112. doi: 10.1056/NEJMoa2019380.
［17］	Alexis A, de Bruin⁃Weller M, Weidinger S, et al. Rapidity of improvement in signs/symptoms of moderate⁃to⁃severe atopic dermatitis by body region with abrocitinib in the phase 3 JADE COMPARE study［J］. Dermatol Ther （Heidelb）, 2022,12（3）:771⁃785. doi: 10.1007/s13555⁃022⁃00694⁃1.
［18］	Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate⁃to⁃severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety （JADE） REGIMEN phase 3 trial［J］. J Am Acad Dermatol, 2022,86（1）:104⁃112. doi: 10. 1016/j.jaad.2021.05.075.
［19］	Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials［J］. J Eur Acad Dermatol Venereol, 2021,35（2）:476⁃485. doi: 10.1111/jdv.16948.
［20］	Katoh N, Ohya Y, Murota H, et al. A phase 3 randomized, multicenter, double⁃blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate⁃to⁃severe atopic dermatitis in Japan （Rising Up）: an interim 24⁃week analysis［J］. JAAD Int, 2022,6:27⁃36. doi: 10.1016/j.jdin.2021.11.001.
［21］	Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate⁃to⁃severe atopic dermatitis from the phaseⅡ and phase Ⅲ clinical trial program［J］. Am J Clin Dermatol, 2021,22（5）:693⁃707. doi: 10.1007/s40257⁃021⁃00618⁃3.
［22］	Torres T, Gonçalo M, Paiva Lopes MJ, et al. Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients［J］. Drugs Context, 2021,10doi: 10.7573/dic.2021⁃9⁃5.
［23］	Mumford BP, Gibson A, Chong AH. Repigmentation of vitiligo with oral baricitinib［J］. Australas J Dermatol, 2020,61（4）:374⁃376. doi: 10.1111/ajd.13348.
［24］	Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase （JAK） 1/JAK2 inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2016,174（6）:1266⁃1276. doi: 10.1111/bjd.14403.
［25］	Gambardella A, Licata G, Calabrese G, et al. Dual efficacy of upadacitinib in 2 patients with concomitant severe atopic dermatitis and alopecia areata［J］. Dermatitis, 2021,32（1S）:e85⁃e86. doi: 10.1097/DER.0000000000000780.
［26］	Bennett M, Moussa A, Sinclair R. Successful treatment of chronic severe alopecia areata with abrocitinib［J］. Australas J Dermatol, 2022,63（2）:274⁃276. doi: 10.1111/ajd.13836.

[1]	Li Hongyi, Wu Panpan, Wu Wenfeng, Peng Junsheng, Liu Qin, Lu Yingshan, Dong Jindian, Yang Zhibo. Clinical efficacy and safety of Luofushan-Baicao oil in the treatment of Aedes albopictus bites: a paired, self-controlled study [J]. Chinese Journal of Dermatology, 2025, 58(2): 178-181.
[2]	Meng Xiao, Wang Junhui, Yan Zhifang, Wang Ning, Cui Bingnan. Evaluation of efficacy of a Chinese herbal mask in the treatment of melanized-type melasma by stereological measurements [J]. Chinese Journal of Dermatology, 2025, 58(1): 53-59.
[3]	Zou Xianbiao, Chen Jinchun, Zeng Yue, Hao Yi. Application of ultrasonography in dermatology: progress and prospects [J]. Chinese Journal of Dermatology, 2024, 57(9): 785-790.
[4]	Xie yuanyuan, Liu Yuzhen, Zeng Rong, . Application of skin imaging techniques in acne vulgaris [J]. Chinese Journal of Dermatology, 2024, 57(8): 757-760.
[5]	Luo Li, Zhang Bona, Wu Wei, Tang Wenjing, Li Yuehua, Liu Xiaoli, Ma Yanan, Li Cuicui, Qi Mengyan, Sun Ni, Shi Qiong. Efficacy and safety of 308-nm excimer laser and 308-nm excimer lamp in the treatment of 194 children with vitiligo: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(8): 721-727.
[6]	Hu Qingjie, Xu Kang, Zhu Hong, Yao Xu. Drug survival rate and safety of dupilumab in the treatment of atopic dermatitis in elderly patients: a retrospective cohort analysis [J]. Chinese Journal of Dermatology, 2024, 57(7): 632-636.
[7]	Zhang Sheng, Wang Xiuwei, Chen Jianyou, Deng Wei, Zhang Haihua, Zhang Gaolei, Liu Xiaoyan, Su Wei. Efficacy of hematoporphyrin monomethyl ether-mediated photodynamic therapy in the treatment of facial port-wine stains in 15 children with Sturge-Weber syndrome [J]. Chinese Journal of Dermatology, 2024, 57(7): 616-622.
[8]	Ge Xinhong, Ma Yingdong, Jiao Yaning, Liu Lingling, Zhou Mei, Zi Wei, Li Bowen. Analysis of efficacy and safety of 532-nm picosecond laser in the treatment of early-stage facial seborrheic keratosis [J]. Chinese Journal of Dermatology, 2024, 57(4): 359-362.
[9]	Zhu Tingting, Zhang Xuejun. Apremilast in the treatment of plaque psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230448-e20230448.
[10]	Yao Wo, Wang Huiying. Lanadelumab in the treatment of hereditary angioedema: a systematic review of clinical trials [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230378-e20230378.
[11]	Yuan Liyan, Yu Xiaoling, Wang Xiaohua, Yang Bin. TYK2 inhibitors for plaque psoriasis: mechanism of action and advances in clinical research [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220740-e0220740.
[12]	Zhao Miaomiao, Yu Peiyao, Yang Haiqian, Yu Yingyao, Ma Li, Mou Wenjia, Shang Yuanyuan. Efficacy, safety, and factors influencing efficacy of omalizumab in the treatment of chronic spontaneous urticaria: a prospective, single-center study [J]. Chinese Journal of Dermatology, 2024, 57(12): 1091-1098.
[13]	Chen Yan, Chen Danyang, Chen Xixue, Shang Panpan, Wang Mingyue. Application of dupilumab in the treatment of 104 patients with bullous pemphigoid and analysis of factors influencing the efficacy [J]. Chinese Journal of Dermatology, 2024, 57(10): 925-930.
[14]	Hu Junyu, Chen Danyang, Chen Xixue, Wang Mingyue. Dupilumab combined with minocycline or with minocycline and systemic glucocorticoids for the treatment of bullous pemphigoid: a cohort study [J]. Chinese Journal of Dermatology, 2024, 57(10): 917-924.
[15]	Guliziba·Tuersun, Qu Yuanyuan. New advances in the treatment of vitiligo with JAK-STAT inhibitors [J]. Chinese Journal of Dermatology, 2024, 57(1): 71-75.

JAK inhibitors for the treatment of moderate-to-severe atopic dermatitis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［26］

Related Articles 15

Metrics

Comments

Recommended 10